AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 210.37B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 6.99B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.48 |
| PE Ratio | 30.30 |
| Forward PE | 17.56 |
| Dividend | 2.43 (1.79%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 1,573,248 |
| Average Volume | 1,934,390 |
| Open | 13,800 |
| Previous Close | 13,592 |
| Day's Range | 13,466 - 13,884 |
| 52-Week Range | 9,574 - 13,884 |
| Beta | 0.17 |
| RSI | 74.87 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Why biotech and drug stocks are on the mend even though the rest of the market is hurting
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.
Roche's $15 Billion Breast Cancer Pill Just Stunned the Market--But AstraZeneca Is Lurking
Roche's $15 Billion Breast Cancer Pill Just Stunned the Market--But AstraZeneca Is Lurking
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India
AstraZeneca Pharma India and Sun Pharmaceutical Industries have joined hands once again, announcing a second brand partnership to expand the...
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus ...
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes
Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don't work equally well in patients with diabetes, a study from India found.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines
London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic data revealed rising unemployment and slowing wage growth, while drugmaker As...
AstraZeneca hits record high, cements lead as UK's biggest stock
Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's position as the largest UK-listed stock by market value.
Why AstraZeneca Stock Was a Winner Today
The company inches closer to bringing a new drug to a very large addressable market.
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca Plc (NASDAQ: AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as wel...
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well ...
AstraZeneca (AZN) Earns FDA Orphan Drug Status for Leukemia Treatment
AstraZeneca (AZN) Earns FDA Orphan Drug Status for Leukemia Treatment
AstraZeneca's Baxdrostat Achieves Major Breakthrough In Hypertension Treatment In Phase III Trial
(RTTNews) - AstraZeneca PLC (AZN, AZN.L) announced results from its Bax24 Phase III trial, revealing that baxdrostat significantly reduced 24-hour systolic blood pressure (SBP) in patients with treatm...
AstraZeneca (AZN) Announces Successful Phase III Trial Results for Baxdrostat
AstraZeneca (AZN) Announces Successful Phase III Trial Results for Baxdrostat
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulat...
Top global stories this week: Diageo, Novo Nordisk, AstraZeneca among notable names
AstraZeneca PLC 2025 Q3 - Results - Earnings Call Presentation
AstraZeneca (AZN) Warns UK on Drug Spending Risks
AstraZeneca (AZN) Warns UK on Drug Spending Risks
AstraZeneca (AZN) Reports Positive Phase III Trial Results for Fasenra
AstraZeneca (AZN) Reports Positive Phase III Trial Results for Fasenra
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the NATRON Phase III trial showed AstraZeneca's FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first...
Why AstraZeneca Stock Topped the Market on Thursday
Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.